1. Home
  2. NAMS vs TBBK Comparison

NAMS vs TBBK Comparison

Compare NAMS & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • TBBK
  • Stock Information
  • Founded
  • NAMS 2019
  • TBBK 1999
  • Country
  • NAMS Netherlands
  • TBBK United States
  • Employees
  • NAMS N/A
  • TBBK N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • TBBK Major Banks
  • Sector
  • NAMS Health Care
  • TBBK Finance
  • Exchange
  • NAMS Nasdaq
  • TBBK Nasdaq
  • Market Cap
  • NAMS 2.7B
  • TBBK 2.6B
  • IPO Year
  • NAMS N/A
  • TBBK 2004
  • Fundamental
  • Price
  • NAMS $23.33
  • TBBK $55.11
  • Analyst Decision
  • NAMS Strong Buy
  • TBBK Buy
  • Analyst Count
  • NAMS 7
  • TBBK 3
  • Target Price
  • NAMS $38.17
  • TBBK $56.33
  • AVG Volume (30 Days)
  • NAMS 538.3K
  • TBBK 395.7K
  • Earning Date
  • NAMS 02-06-2025
  • TBBK 01-30-2025
  • Dividend Yield
  • NAMS N/A
  • TBBK N/A
  • EPS Growth
  • NAMS N/A
  • TBBK 16.50
  • EPS
  • NAMS N/A
  • TBBK 3.95
  • Revenue
  • NAMS $33,594,000.00
  • TBBK $472,068,000.00
  • Revenue This Year
  • NAMS $131.53
  • TBBK N/A
  • Revenue Next Year
  • NAMS N/A
  • TBBK $10.40
  • P/E Ratio
  • NAMS N/A
  • TBBK $14.10
  • Revenue Growth
  • NAMS 78.77
  • TBBK 6.73
  • 52 Week Low
  • NAMS $15.19
  • TBBK $29.92
  • 52 Week High
  • NAMS $27.29
  • TBBK $61.17
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 44.28
  • TBBK 55.11
  • Support Level
  • NAMS $23.17
  • TBBK $54.19
  • Resistance Level
  • NAMS $26.71
  • TBBK $57.24
  • Average True Range (ATR)
  • NAMS 0.94
  • TBBK 1.62
  • MACD
  • NAMS -0.40
  • TBBK 0.47
  • Stochastic Oscillator
  • NAMS 23.65
  • TBBK 77.13

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.

Share on Social Networks: